Assessment of tumor growth factor‑β1 neutralizing antibody in the treatment of allergic rhinitis and asthma
- Yan Wei
- Zhili Zhang
- Feng Wang
- Shuihong Zhou
Published online on: November 13, 2017
Copyright: © Wei et al.
This is an open access article distributed under the terms of Creative Commons Attribution License.
To identify a novel and effective therapy for allergic rhinitis and asthma (ARA), the present study focused on treatment with tumor growth factor (TGF)‑β1 neutralizing antibody. In the present study, four medications were administered to mice with ovalbumin‑induced allergic inflammation. Allergic symptoms in the lungs and nasal mucosa were evaluated by detecting the secretion of cytokines from helper T cells (Th) in the peripheral blood, nasal lavage fluid and bronchoalveolar lavage fluid using ELISA. Defects in regulatory T (Treg) cells in peripheral blood mononuclear cells were also detected using flow cytometry. Furthermore, the expression of TGF‑β1 and activation of Smad2/3 pathways were assessed using immunohistochemical staining, reverse transcription‑quantitative polymerase chain reaction, and western blotting. It was observed that TGF‑β1 neutralizing antibody inhibited symptoms of inflammation in the upper and lower airways. TGF‑β1 neutralizing antibody also restored the Th1/Th2 balance and ameliorated Treg cell defects induced by ARA. Furthermore, the therapeutic effects of TGF‑β1 neutralizing antibody were related to its inhibitory effects on TGF‑β1 expression and Smad2/3 signaling in nasal and lung tissues. Therefore, TGF‑β1 neutralizing antibody may be an effective medicine for the treatment of ARA.